Evidence map›Paper›PMID 39115368›Full record

ArticleCancer immunology research2024

The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma.

Lucy B Van Kleunen, Mansooreh Ahmadian, Miriam D Post, Rebecca J Wolsky, Christian Rickert, Kimberly R Jordan, Junxiao Hu, Jennifer K Richer, Lindsay W Brubaker, Nicole Marjon and 4 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Lucy B Van KleunenDepartment of Computer Science, University of Colorado, Boulder, Colorado.ORCID 0000-0003-4422-712X
Mansooreh AhmadianDepartment of Biostatistics and Informatics, Colorado School of Public Health, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-5020-3979
Miriam D PostDepartment of Pathology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-7220-8247
Rebecca J WolskyDepartment of Pathology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-3721-2448
Christian RickertDepartment of Immunology and Microbiology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-7396-4335
Kimberly R JordanDepartment of Immunology and Microbiology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-8380-7157
Junxiao HuDepartment of Pediatrics, Cancer Center Biostatistics Core, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-5937-7916
Jennifer K RicherDepartment of Pathology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-9960-0991
Lindsay W BrubakerDepartment of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-8986-2915
Nicole MarjonDepartment of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-9963-5943
Kian BehbakhtDepartment of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-4793-9958
Matthew J SikoraDepartment of Pathology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-2915-7442
Benjamin G BitlerDepartment of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-5809-5271
Aaron ClausetDepartment of Computer Science, University of Colorado, Boulder, Colorado.ORCID 0000-0002-3529-8746

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparitiesR01CA285446 · NCI · UNIVERSITY OF COLORADO DENVER · PI Benjamin G Bitler, Matthew J Sikora · 2023 to 2026
$2.4M
Targeting Wnt signaling in therapy-resistant ovarian cancerR37CA261987 · NCI · UNIVERSITY OF COLORADO DENVER · PI Benjamin G Bitler · 2021 to 2026
$2.4M
American Cancer Society (ACS) RSG-19-129-01-DDCNational Institutes of Health (NIH) R37CA261987NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA285446NCI NIH HHS R37 CA261987Ovarian Cancer Research Alliance (OCRA) CRDG - 2022 -
6 · The paper itself

Abstract

Ovarian cancer is the deadliest gynecologic malignancy, and therapeutic options and mortality rates over the last three decades have largely not changed. Recent studies indicate that the composition of the tumor immune microenvironment (TIME) influences patient outcomes. To improve spatial understanding of the TIME, we performed multiplexed ion beam imaging on 83 human high-grade serous carcinoma tumor samples, identifying approximately 160,000 cells across 23 cell types. From the 77 of these samples that met inclusion criteria, we generated composition features based on cell type proportions, spatial features based on the distances between cell types, and spatial network features representing cell interactions and cell clustering patterns, which we linked to traditional clinical and IHC variables and patient overall survival (OS) and progression-free survival (PFS) outcomes. Among these features, we found several significant univariate correlations, including B-cell contact with M1 macrophages (OS HR = 0.696; P = 0.011; PFS HR = 0.734; P = 0.039). We then used high-dimensional random forest models to evaluate out-of-sample predictive performance for OS and PFS outcomes and to derive relative feature importance scores for each feature. The top model for predicting low or high PFS used TIME composition and spatial features and achieved an average AUC score of 0.71. The results demonstrate the importance of spatial structure in understanding how the TIME contributes to treatment outcomes. Furthermore, the present study provides a generalizable roadmap for spatial analyses of the TIME in ovarian cancer research.

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsTumor MicroenvironmentAgedFemaleHumansMiddle AgedNeoplasm GradingPrognosis

Identifiers

PMID39115368
PMCPMC11534564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.